FDA Approves Carfilzomib Combination for Patients with Relapsed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) approved carfilzomib in combination with lenalidomide and dexamethasone as a treatment for relapsed multiple myeloma. A large clinical trial showed improved progression-free survival in patients who received the carfilzomib combination compared to patients who only received lenalidomide and dexamethasone. Read more here.
To learn more about clinical trials, visit My PearlPoint.